Celltech achieves osteoporosis collaboration with Amgen
Celltech has achieved a further milestone in its agreement with Amgen for the research, development and global commercialisation of novel treatments for osteoporosis using Celltech's proprietary antibody fragment technology, which aims to identify antibody fragments against sclerostin, a protein discovered by Celltech.
Celltech has achieved a further milestone in its agreement with Amgen for the research, development and global commercialisation of novel treatments for osteoporosis using Celltech's proprietary antibody fragment technology, which aims to identify antibody fragments against sclerostin, a protein discovered by Celltech.
Sclerostin is involved in the regulation of bone deposition, and it is believed that by inhibiting this protein, bone loss in osteoporosis patients may be reversed.
Amgen and Celltech have completed their studies in certain disease models, triggering an undisclosed milestone payment to Celltech. This achievement follows rapidly on from a previous research milestone in October 2003.
Dr Melanie Lee, research and development director for Celltech, commented: 'We are delighted with the rapid progress being achieved by Amgen and Celltech scientists in this innovative programme, and continue to be highly encouraged by the data generated in studies to date.'